GIP: Glucose-dependent Insulinotropic Peptide

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Aging (NIA)
• Treatments: Gastric Inhibitory Polypeptide

Criteria

Inclusion Criteria:

• 18 years of age and older

• Healthy Type 2 Diabetics

• Agree to stay off glucosidases for 3 days prior to infusion visits (Examples: Precose, Glyset)

• Agree to stay off Sulfonylureas 5 days prior to infusion visits (Examples: Glucotrol, Amaryl, glyburide, metformin

• Able to ingest 1000 mg Tylenol on study visits

• Able to consume study breakfast consisting of scrambled egg, white toast with margarine, corn flakes, 2% milk, banana at each infusion visit

• Female participants must have Hct > 36

• Male participant must have Hct > 38

• No kidney or liver disease per history and evidenced by blood and urine tests

• Physical Exam and EKG that do not contraindicate patient to be in the study

Exclusion Criteria:

• Taking the following medications: Insulin, or Thiazolidinediones, i.e. Avandia, Actos

• Pregnancy

• Steroid use within the past 3 months

• Recent infection, fever or chills